Recently, Russo Partners coordinated the launch of a newly redesigned website for Thrombolytic Science International (TSI). The company is currently developing a new-generation, clot-dissolving therapy, TS01, to treat patients with acute ischemic stroke, an area with a high level of unmet need.
In addition to new web copy, which can be viewed here, the redesigned website also features an illustration demonstrating the mechanism behind TS01’s specificity for only the types of clots that cause strokes and heart attacks (view the graphic here).
Approximately 90% of all strokes are caused by a blood clot, however no satisfactory clot-dissolving treatment exists. TS01 potentially addresses the limitations of the only approved clot-dissolving drug, rtPA, which has a short treatment time window, suboptimal efficacy and carries a risk of intra-cranial hemorrhage. As a result, only about 5% of patients with acute ischemic strokes receive this therapy. TSI plans on initiating a Phase 1 clinical study evaluating TS01 in healthy adults in the third quarter of 2012.
Russo Partners provided recommendations as well as feedback related to the design and development of the 3D graphic illustrating the mechanism TS01’s specificity. In addition, Russo Partners coordinated the redesign of the new site and provided support in the development of the updated web copy.
